Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169482 | 0.84 | ALDH1A1 (0.45) | L3MBTL1HDAC1HDAC4HDAC6HDAC2 | |
| SCHEMBL4166897 | 0.83 | PADI4 (0.41) | ROCK2HDAC1HDAC2 | |
| SCHEMBL4156708 | 0.79 | CCKBR (0.34) | HDAC1HDAC4HDAC6HDAC2MAPK14 | |
| SCHEMBL5121747 | 0.76 | HDAC1 (0.45) | ROCK2L3MBTL1HDAC1HDAC4HDAC6 | |
| SCHEMBL27715247 | 0.76 | HDAC1 (0.45) | ROCK2L3MBTL1HDAC1HDAC4HDAC6 | |
| SCHEMBL4159878 | 0.75 | ROCK2 (0.45) | ROCK2HDAC1HDAC2 | |
| SCHEMBL4166903 | 0.75 | CES1 (0.36) | ROCK2HDAC1HDAC2 | |
| SCHEMBL4165139 | 0.74 | HDAC1 (0.41) | L3MBTL1HDAC1HDAC4HDAC6HDAC2 | |
| SCHEMBL4174424 | 0.73 | SIGMAR1 (0.38) | L3MBTL1HDAC1HDAC4HDAC6HDAC2 | |
| SCHEMBL4156148 | 0.72 | CES1 (0.31) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054448-A1 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors | JONES PHILIP | 2009-02-26 | — | — | US | disclosed |
| EP-1945609-A2 | AMINO ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007029036-A2 | AMINO ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054448-A1 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC5, HDAC1, HDAC11 | ROCK2 2524/4885L3MBTL1 3032/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.